Which psoriasis cream causes less skin discoloration? new study aims to find out
NCT ID NCT05981118
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times
Summary
This study compares two standard psoriasis creams—a steroid and a newer drug called tapinarof—to see which one causes less skin color change after treatment. Forty adults with darker skin types will use one cream daily on their legs for up to 12 weeks. Researchers will track pigmentation changes, redness, and dryness to help doctors choose the best option for reducing lasting marks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Betamethasone dipropionate 0.05% cream and tapinarof 1% cream
- What this could lead to
- If successful, this study could help doctors choose a psoriasis treatment that leaves less lasting skin discoloration, especially for people with darker skin tones.
- What could go wrong
- This is a small, early-phase study with only 40 participants, so results may not apply to everyone. It compares two existing treatments, so no new drug is being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2024
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adults (age 18+) with Fitzpatrick skin type 3 or higher who have been diagnosed with ICD10 code L40.9 for psoriasis between \[dates\] at Atrium Health Wake Forest Baptist Medical Center. 2. Stable on other therapies such as biologics for at least 3 months before randomization. Exclusion Criteria: 1. Lack of a diagnosis of psoriasis (ICD10 code L40.9) or Fitzpatrick skin type below 3. 2. Pigmentary changes that in the opinion of the investigator would compromise the ability to assess the study outcomes.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ICD10 code L40.9 for psoriasis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Wake Forest University Health Sciences Department of Dermatology
Winston-Salem, North Carolina, 27157, United States